Peptide Companion
Back to catalog
Peptide Companion
single
Healing & Recovery
Vial: 30 mg

PNC-27 (30 mg Vial)

PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 complexes. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Detailed protocol below.

Dosing Schedule
WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–2100 mcg (0.10 mg)1 unit (0.01 mL)
Weeks 3–4200 mcg (0.20 mg)2 units (0.02 mL)
Weeks 5–8300 mcg (0.30 mg)3 units (0.03 mL)
Weeks 9–12400 mcg (0.40 mg)4 units (0.04 mL)
Weeks 13–16500 mcg (0.50 mg)5 units (0.05 mL)
Supplies Needed
  • •Peptide Vials (PNC-27, 30 mg each):
  • •Insulin Syringes (U‑100 or 30/50‑unit for precision):
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
References

  • Journal of Biomedical Science (2017)

    Review of therapeutic peptides; PNC-27 mechanism and cancer cell selectivity

    View source

  • Cancer Chemotherapy and Pharmacology (2010)

    PNC-27 induces tumor cell membrane lysis; preclinical mechanism study

    View source

  • FDA Drug Safety Communication (2015)

    Warning: PNC-27 is unapproved; safety not established

    View source

  • International Journal of Cancer (2006)

    PNC-28 (related peptide) blocks pancreatic cancer growth in vivo; mouse model study

    View source

  • Peptide Sciences

    Peptide storage guidelines: lyophilized and reconstituted stability

    View source

  • BMC Cancer (2008)

    PNC-27 selectively kills cancer cells via HDM-2 binding and membrane disruption

    View source

  • PubMed (2012)

    PNC-27 peptide induces necrosis via direct membrane lysis mechanism

    View source

  • CDC

    Vaccine administration: subcutaneous route (angle/site guidance)

    View source

  • National Hemophilia Foundation (2021)

    Subcutaneous injection guidelines: needle length, angle, site preparation

    View source

  • NCBI Bookshelf

    Best practices for injection (asepsis, preparation, and administration)

    View source

  • Subcutaneous Drug Injection Review (PMC)

    Pharmacologic considerations of the subcutaneous route

    View source

Educational content adapted from peptidedosages.com. Not medical advice.